Sanofi (SNYNF)
| Market Cap | 115.96B |
| Revenue (ttm) | 53.89B |
| Net Income (ttm) | 10.69B |
| Shares Out | n/a |
| EPS (ttm) | 8.67 |
| PE Ratio | 10.85 |
| Forward PE | 9.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 171,500 |
| Average Volume | 16,716 |
| Open | 96.34 |
| Previous Close | 97.09 |
| Day's Range | 96.34 - 96.34 |
| 52-Week Range | 90.05 - 122.03 |
| Beta | 0.37 |
| RSI | 38.68 |
| Earnings Date | Jan 29, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial numbers in EUR Financial StatementsNews
SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib, and a phase III study fails to hit its primary endpoint.
Sanofi (SAN) Secures Exclusive Rights to Alzheimer's Therapy ADEL-Y01
Sanofi (SAN) Secures Exclusive Rights to Alzheimer's Therapy ADEL-Y01
Sanofi in up to $1B deal with South Korean biotech for Alzheimer's candidate
South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi
South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to develop and sell the biotech company's experimental Alzheimer's disease treat...
Sanofi: Today's Tolebrutinib Setback Shouldn't Worry Shareholders - This Is Why
Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration
Dren Bio, a privately held, clinical-stage biotechnology company, has a new collaboration with Sanofi SA (NASDAQ: SNY). The new agreement is built on the existing relationship between the two compani...
Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration
Dren Bio, a privately held, clinical-stage biotechnology company, has a new collaboration with Sanofi SA (NASDAQ: SNY). The new agreement is built on the existing relationship between the two companie...
Sanofi (SNY) Enters $1.7B Deal with Dren Bio for Antibody Therapies
Sanofi (SNY) Enters $1.7B Deal with Dren Bio for Antibody Therapies
Sanofi in deal worth up to $1.7B with Dren Bio for autoimmune disease treatments
Sanofi partners with Dren Bio on multispecific antibody therapies in a deal worth up to $1.7B. Read more here.
Dren Bio to collaborate with Sanofi to develop autoimmune disease therapies for up to $1.7 billion
Dren Bio, a private biotech company, said on Monday it has entered into a strategic collaboration with Sanofi to develop therapies for autoimmune diseases in a deal worth up to $1.7 billion.
Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy
SAN CARLOS, Calif.--(BUSINESS WIRE)--Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy.
Sanofi's Multiple Sclerosis Drug Faces Trial And Regulatory Setbacks
Sanofi said its Phase 3 PERSEUS ... Full story available on Benzinga.com
Sanofi (SNY) Phase 3 Study Results Impact Regulatory Plans
Sanofi (SNY) Phase 3 Study Results Impact Regulatory Plans
Sanofi (SNY) Expects Extended FDA Review for Tolebrutinib in MS Treatment
Sanofi (SNY) Expects Extended FDA Review for Tolebrutinib in MS Treatment
Sanofi shares slide as FDA delays MS drug decision and late-stage trial disappoints
Shares of French pharmaceutical group Sanofi fell sharply on Monday after the company flagged another delay to a US regulatory decision for its experimental multiple sclerosis drug tolebrutinib and re...
Sanofi stock slumps after two setbacks on multiple-sclerosis drug
Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the year and that a trial for a different form ...
Sanofi flags delay in FDA's decision on tolebrutinib, shares fall
French pharmaceutical group Sanofi said on Monday the U.S. Food and Drug Administration's decision on its investigative drug to treat multiple sclerosis was expected to be delayed until the first quar...
Sanofi (SNY) Halts Regulatory Plans for Tolebrutinib in PPMS
Sanofi (SNY) Halts Regulatory Plans for Tolebrutinib in PPMS
Sanofi’s tolebrutinib falls short in phase 3 PERSEUS trial for primary progressive multiple sclerosis
Understood! Please provide the article for which you would like me to generate an SEO-friendly meta description.
Sanofi Multiple Sclerosis Drug Hit by Double Setback
A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of the disease didn't hit its main goal.
Sanofi: Regulatory Decision For Tolebrutinib To Be Delayed
(RTTNews) - Sanofi (SNY, SAN.PA) said it anticipates that the review process for the US regulatory review of tolebrutinib in non-relapsing secondary progressive multiple sclerosis will extend beyond t...
Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to o...
Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated regu...
Sanofi Scores Two Major China Approvals For Rare Blood Disorder Drugs
The National Medical Products Administration (NMPA) in China has approved Sanofi SA’s (NASDAQ: SNY) two medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplac...
Sanofi Scores Two Major China Approvals For Rare Blood Disorder Drugs
The National Medical Products Administration (NMPA) in China has approved Sanofi SA's (NASDAQ: SNY) two medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplaci...